摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1H-spiro[benzo[b][1,5,4]oxathiazecine-3,1'-cyclopropane]2,2-dioxide | 1287794-60-8

中文名称
——
中文别名
——
英文名称
10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1H-spiro[benzo[b][1,5,4]oxathiazecine-3,1'-cyclopropane]2,2-dioxide
英文别名
10,11-difluoro-12-(2-fluoro-4-iodoanilino)-2,2-dioxospiro[4,5,6,7-tetrahydro-1H-8,2lambda6,1-benzoxathiazecine-3,1'-cyclopropane]-5,6-diol;10,11-difluoro-12-(2-fluoro-4-iodoanilino)-2,2-dioxospiro[4,5,6,7-tetrahydro-1H-8,2λ6,1-benzoxathiazecine-3,1'-cyclopropane]-5,6-diol
10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1H-spiro[benzo[b][1,5,4]oxathiazecine-3,1'-cyclopropane]2,2-dioxide化学式
CAS
1287794-60-8
化学式
C19H18F3IN2O5S
mdl
——
分子量
570.328
InChiKey
FENWEVRRFMFDBS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    31
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.37
  • 拓扑面积:
    116
  • 氢给体数:
    4
  • 氢受体数:
    10

反应信息

  • 作为产物:
    描述:
    benzenamine, 2,3-difluoro-N-(2-fluoro-4-iodophenyl)-6-nitro-5-(2-propen-1-yloxy) 在 吡啶4-二甲氨基吡啶四氧化锇 、 3-phenyl-1H-inden-1-ylidene[bis(i-butylphoban)]ruthenium(II) dichloride 、 N-甲基吗啉氧化物 作用下, 以 四氢呋喃二氯甲烷 为溶剂, 反应 103.0h, 生成 10,11-difluoro-12-((2-fluoro-4-iodophenyl)amino)-5,6-dihydroxy-4,5,6,7-tetrahydro-1H-spiro[benzo[b][1,5,4]oxathiazecine-3,1'-cyclopropane]2,2-dioxide
    参考文献:
    名称:
    Macrocyclic MEK1/2 inhibitor with efficacy in a mouse model of cardiomyopathy caused by lamin A/C gene mutation
    摘要:
    Signaling mediated by extracellular signal-regulated kinases I and 2 (ERK1/2) is involved in numerous cellular processes. Mitogen-activated protein kinase kinases (MEK1/2) catalyze the phosphorylation of ERK1/2, converting it into an active kinase that regulates the expression of numerous genes and cellular processes. Inhibitors of MEK1/2 have demonstrated preclinical and clinical efficacy in certain cancers and types of cardiomyopathy. We report the synthesis of a novel, allosteric, macrocyclic MEK1/2 inhibitor that potently inhibits ERIC1/2 activity in cultured cells and tissues of mice after systemic administration. Mice with dilated cardiomyopathy caused by a lamin A/C gene mutation have abnormally increased cardiac ERK1/2 activity. In these mice, this novel MEK1/2 inhibitor is well tolerated, improves left ventricular systolic function, decreases left ventricular fibrosis, has beneficial effects on skeletal muscle structure and pathology and prolongs survival. The novel MEK1/2 inhibitor described herein may therefore find clinical utility in the treatment of this rare cardiomyopathy, other types of cardiomyopathy and cancers in humans. (C) 2016 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2016.12.014
点击查看最新优质反应信息

文献信息

  • NOVEL MEK INHIBITORS USEFUL IN THE TREATMENT OF DISEASES
    申请人:Khire Uday R.
    公开号:US20120208859A1
    公开(公告)日:2012-08-16
    The invention pertains to compound of Formula (I) wherein X, Y, Z, R 1 , R 2 , R 3 , R 4 , A and A′ are as described hereinabove. Formula (I) and (II) compounds can be used in pharmaceutical compositions, useful for the treatment of diseases.
    本发明涉及式(I)的化合物,其中X,Y,Z,R1,R2,R3,R4,A和A'如上所述。式(I)和(II)化合物可用于制备药物组合物,用于治疗疾病。
  • NOVEL MEK INHIBITORS FOR TREATING CARDIOMYOPATHIES AND RELATED CONDITIONS
    申请人:Allomek Therapeutics LLC
    公开号:US20150250762A1
    公开(公告)日:2015-09-10
    The invention pertains to compound of Formula (I) wherein X, Y, Z, R1, R2, R3, R4, A, and A′ are described herein. Formula (I) compounds can be used in pharmaceutical compositions, useful for the treatment of disease, in particular cardiovascular conditions and more particularly cardiomyopathies, as well as other related conditions.
    本发明涉及式(I)化合物,其中X、Y、Z、R1、R2、R3、R4、A和A'的描述在此处。式(I)化合物可用于制备药物组合物,用于治疗疾病,特别是心血管疾病,更特别是心肌病,以及其他相关疾病。
  • [EN] NOVEL MEK INHIBITORS, USEFUL IN THE TREATMENT OF DISEASES<br/>[FR] NOUVEAUX INHIBITEURS DE MEK, UTILES DANS LE TRAITEMENT DES MALADIES
    申请人:ALLOSTEM THERAPEUTICS LLC
    公开号:WO2011047055A8
    公开(公告)日:2012-05-24
  • NOVEL MEK INHIBITORS, USEFUL IN THE TREATMENT OF DISEASES
    申请人:Allostem Therapeutics LLC
    公开号:EP2488507B1
    公开(公告)日:2014-12-17
  • US9034861B2
    申请人:——
    公开号:US9034861B2
    公开(公告)日:2015-05-19
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐